
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage biopharmaceutical company with positive outlook due to its use of precision medicine in developing anti-cancer therapeutics, specifically its lead program Stenoparib which has shown promising results in advanced ovarian cancer and is now being trialed for recurrent Small Cell Lung Cancer. The company's proprietary Drug Response Predictor (DRP) platform and Stenoparib DRP companion diagnostic give it a competitive advantage in identifying and selecting patients for enrollment, and the large market potential for PARP inhibitors in multiple oncology indications provides strong potential for growth. Additionally, the company has a solid balance sheet with enough cash to support its operations into late 2026.
Bears say
Allarity Therapeutics is a clinical stage, precision medicine pharmaceutical company that focuses on developing anti-cancer therapeutics, with a lead program in developing Stenoparib for ovarian cancer. The company has faced challenges in its development with recent negative adjustments to EPS estimates. Although the company's DRP platform has shown potential for personalized and precision medicine, the high risks and long development timeline for Stenoparib may outweigh potential rewards, especially considering the large market potential for PARP inhibitors in the treatment of multiple cancers. Additionally, the company's financials revealed minimal revenue and substantial loss, raising concerns about the sustainability of its operations.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares